Wall Street attention to AbbVie Inc. often is driven by three near-term topics – its struggle for supremacy in the hepatitis C space against Gilead Sciences Inc. and Merck & Co. Inc., its oncology strategy and the looming 2019 patent expiry of autoimmune colossus Humira (adalimumab). During a June 3 R&D day presentation, management played to all three concerns, highlighting its oncology portfolio and a pair of Phase III immunology candidates that could make the post-Humira horizon a bit sunnier.
Beyond Humira: How AbbVie Plans To Hold Its Immunology Leadership Reign
AbbVie detailed plans for a pair of late-stage immunology candidates – an anti-IL-23 drug and a JAK1 inhibitor – that it says point to a bright future in immunology after Humira's patent expires during an R&D day.
More from United States
More from North America
• By
In discussing FDA’s adverse event monitoring, Makary also seemed to falsely imply the agency did not fully investigate the myocarditis signal with COVID-19 vaccines.
• By
The preliminary White House 2026 budget plan cuts agency funding, but not so sharply that user fees are excluded from collection.
• By
An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Pink Sheet's sister publication Scrip about the latest developments.